• Policy
• MFDS reviews COVID-19 drugs Xocova and Lagevrio
• by Lee, Hye-Kyung Aug 21, 2024 05:47am

• Company
• Celltrion Pharm announces vision to become ‘Top 5'
• by Kim, Jin-Gu Aug 20, 2024 06:34am

• Company
• 'Trodelvy' approved for prescription at general hospitals
• by Eo, Yun-Ho Aug 20, 2024 06:34am

• Company
• Reimb remains an issue despite broadened options for UC
• by Moon, sung-ho Aug 20, 2024 06:34am

• Company
• K-Pharma focuses on developing CAR-NK cell therapies
• by Son, Hyung-Min Aug 20, 2024 06:34am

• Policy
• New criteria set for flexible ICER threshold evaluations
• by Lee, Tak-Sun Aug 20, 2024 06:34am

• Policy
• KDCA apologizes for COVID-19 drug shortages
• by Lee, Hye-Kyung Aug 19, 2024 05:47am

• Company
• Will Handok’s Empaveli be reimbursed in 1H in KOR?
• by Eo, Yun-Ho Aug 19, 2024 05:47am

• Company
• Will Astellas’ gastric cancer drug Vyloy be approved in 2H?
• by Eo, Yun-Ho Aug 19, 2024 05:47am

• Company
• Entresto faces competition in the heart failure market
• by Moon, sung-ho Aug 19, 2024 05:47am